New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
08:11 EDTSQNM, MDAS, DSCI, CCRN, HITK, AEZS, AMED, IMGN, HTWR, CRVLOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 13 at 7:45 am; not all presentations may be webcasted. Webcast Link
News For AMED;DSCI;CRVL;AEZS;MDAS;HTWR;HITK;SQNM;IMGN;CCRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2015
07:19 EDTHTWRHeartWare sold 773 HeartWave HVAD systems globally
Subscribe for More Information
07:19 EDTHTWRHeartWare reports Q2 non-GAAP EPS (47c), consensus (49c)
Reports Q2 revenue $73.6M, consensus $71.87M
July 29, 2015
16:29 EDTMDASMedAssets sees FY15 EPS $1.20-$1.26, consensus $1.19
Sees FY15 revenue $756M-$768M, consensus $759.58M. The company raised the midpoints of its full-year 2015 consolidated financial guidance, realigned the segment revenue mix based on year-to-date results, and narrowed the guidance ranges.
16:27 EDTMDASMedAssets reports Q2 EPS 31c, consensus 27c
Subscribe for More Information
13:05 EDTCCRNCross Country Healthcare agrees to sell education business for $8M
Subscribe for More Information
08:29 EDTIMGNImmunoGen price target raised to $24 from $13 at Oppenheimer
Oppenheimer hiked its price target on ImmunoGen as the firm thinks that updates on its '853 drug will better frame the drug's value. The firm believes that several other positive catalysts will propel the stock higher in 2016. It keeps an Outperform rating on the shares.
07:42 EDTAEZSAeterna Zentaris selects optimized Erk inhibitor for cancer therapy development
Subscribe for More Information
07:07 EDTAMEDAmedisys reports Q2 adjusting EPS 32c, consensus 33c
Reports Q2 revenue $314.1M, consensus $307.11M.
July 28, 2015
07:35 EDTAEZSAeterna Zentaris grants entrepreneurs option for tumor vaccine technology
Subscribe for More Information
July 27, 2015
07:37 EDTAEZSAeterna Zentaris starts promoting Saizen for injection in 25 U.S. territories
Subscribe for More Information
July 23, 2015
09:10 EDTHTWRNorthland sees HeartWare takeover as 'highly unlikely
Northland analyst Suraj Kalia believes the sympathy rally in shares of HeartWare (HTWR) after St. Jude Medical (STJ) announced the acquisition of Thoratec (THOR) could be short lived. HeartWare has already tried to sell itself to larger medical device companies over the past few years, Kalia tells investors in a research note, citing his own field work. He views a buyout of HeartWare at this stage as "highly unlikely" and feels speculation of a $102-$122 per share takeover price is based on "na´ve and unsophisticated" analysis. Kalia keeps an Underperform rating on HeartWare with a $60 price target. The maker of implantable heart pumps, following a two-day rally, closed yesterday at $88.21.
July 21, 2015
16:28 EDTHTWROn The Fly: Top stock stories for Tuesday
Subscribe for More Information
15:08 EDTHTWRThoratec reaches all-time high after report of St. Jude takeover
Subscribe for More Information
12:40 EDTHTWRSt. Jude in talks to acquire Thoratec, Bloomberg reports
St. Jude Medical (STJ) is in talks to acquire Thoratec (THOR), Bloomberg reports, citing people familiar with the situation. Talks are ongoing and could still fall apart as no deal has been reached, Bloomberg adds. Thoratec shares spiked early in today's session, but a catalyst for the move was unclear before the Bloomberg report. Shares of the medical device maker focused on advanced heart failure patients are up $9.52 to $58.33 in midday trading. Its close competitor HeartWare (HTWR) is now up $5.53 to $84.70. Shares of St. Jude are up 4 to $76.61. Reference Link
12:33 EDTHTWRThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
10:20 EDTHTWRCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
10:01 EDTMDASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:58 EDTHTWRThoratec jumps 14% to $55.82 in early trading
Subscribe for More Information
06:04 EDTMDASMedAssets downgraded to Market Perform from Outperform at Cowen
Cowen downgraded MedAssets to Market Perform and lowered its price target to $22 from $25. The firm believes shares reflect optimism around a transformative corporate event such as a split between the SCM and RCM segments, that is less likely to happen.
July 20, 2015
07:10 EDTHTWRHeartWare begins its MVAD System CE Mark international clinical trial
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use